Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel

• Published in: BMC pulmonary medicine Vol. 16; no. 8; p. 7
• Main Authors: Morell, Ferran, Esser, Dirk, Lim, Jonathan, Stowasser, Susanne, Villacampa, Alba, Nieves, Diana, Brosa, Max
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.01.2016; BioMed Central
• Subjects: Bacterial pneumonia; Care and treatment; Complications and side effects; Costs and Cost Analysis; Delphi Technique; Development and progression; Disease Progression; Health aspects; Health Care Costs; Health Resources - economics; Health Resources - utilization; Humans; Idiopathic Pulmonary Fibrosis - diagnosis; Idiopathic Pulmonary Fibrosis - economics; Idiopathic Pulmonary Fibrosis - therapy; Immunosuppressive agents; Pneumonia; Practice Patterns, Physicians' - economics; Practice Patterns, Physicians' - statistics & numerical data; Pulmonary fibrosis; Pulmonary Medicine; Pulmonology; Risk factors; Spain; State Medicine - economics; Spain
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-016-0168-6

Idiopathic pulmonary fibrosis (IPF) is a form of chronic fibrosing interstitial pneumonia characterized by progressive worsening of dyspnea and lung function, with a poor prognosis. The objective of this study was to determine treatment patterns, resource use and costs of managing Spanish patients with IPF. A three-round Delphi consensus panel of 15 clinical experts was held between December 2012 and June 2013 using questionnaires to describe the management of patients with IPF. A cost analysis based on Delphi panel estimates was made from the Spanish National Health System (NHS) perspective, including the direct costs of IPF diagnosis and management. Unit costs were applied to Delphi panel estimates of health resource use. Univariate sensitivity analyses were made to evaluate uncertainties in parameters. The Delphi panel estimated that 20, 60 and 20% of IPF patients presented with stable disease, slow and rapid disease progression, respectively. The estimated annual cost per patient with stable disease, slow and rapid disease progression was €11,484, €20,978 and €57,759, respectively. This corresponds to a weighted average annual cost of €26,435 with itemized costs of €1,184 (4.5), €7,147 (27.0), €5,950 (22.5), €11,666 (44.1) and €488 (1.9%) for the diagnosis of IPF, treatment, monitoring, management of acute exacerbations and end-of-life care, respectively. The parameter that varied the annual cost per patient the most was resource use associated with acute exacerbations. The management of patients with IPF in Spain, especially patients with rapid disease progression, has a high economic impact on the NHS.